Navigation Links
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Date:12/6/2011

THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in the safety monitoring program, called the Nplate® NEXUS (Network of EXperts Understanding and Supporting Nplate and Patients) Program, in order to prescribe or receive Nplate. 

"The goals of the Nplate® NEXUS Program were to educate physicians and patients about treatment risks and benefits, and to define the long-term safety profile of Nplate," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "The FDA has now concluded that enrollment in a restricted distribution program is no longer necessary to prescribe or receive Nplate. Amgen will continue to monitor the safety profile of Nplate through clinical trials and post-marketing pharmacovigilance programs."

The primary modification of the REMS is the removal of the elements to assure safe use; however, a modified REMS communication plan will remain in place.  In addition, the Medication Guide will no longer be part of the REMS, but will be part of approved product labeling.

From 2008 to 2011, the Nplate® NEXUS Program has collected long-term safety data from more than 5,200 patients. The restrictive elements of the REMS included enrollment of prescribers, patients and institutions to assist in collecting long-term safety information. Upon further review, the FDA and Amgen have determined that the safety information collected through the REMS, which is based on individual case safety reports, is inherently confounded by underlying medical conditions in the treated patient population and thus cannot be us
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
2. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
3. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
4. Amgen Announces 2011 Fourth Quarter Dividend
5. Amgen to Present at the UBS Global Life Sciences Conference
6. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
7. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
8. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
9. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
10. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
11. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 As the world ... no room for doubt that this century would mark the ... the field of medicine science. The fact that the world ... not unknown to the scientific community. Almost half of these ... therefore can be prevented with medical care and intervention. While ...
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
Breaking Biology Technology:Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Array Architects Challenges Staff to Create with 3D Printer 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Digital Agency Studio PMG Launches New Case Studies on Website 2
... Contract Research Organization Exceeds Expectations, MEMPHIS, ... Contract Research,Organization exclusively focused on oncology, announced ... exceeded projections as the company continues,to experience ... to,ACORN,s ability to consistently exceed client expectations, ...
... Pharma, Inc., a,diversified specialty pharmaceutical company, announced ... issues in the treatment of moderate to,severe ... dry eye medication Lacrisert(R),(hydroxypropyl cellulose ophthalmic insert), ... helps to retain,moisture, stabilize the tear film, ...
... -- 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company ... primarily in China,today announced that it has filed ... for approval of NuLeusin for the treatment of ... is expected to,be the only treatment of this ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
(Date:10/1/2014)... , October 1, 2014 ... in the life science field  The ... come and go over the years. Some are ... Photon upconversion is a novel detection technology that ... years. Now, finally, this technology is becoming commercially ...
(Date:10/1/2014)... prairies and forests of the world can also be ... to a surprising new study led by Colorado State ... The research team analyzed 596 soil samples collected from ... diversity of below-ground life, most of which had never ... 16.2 percent of the organisms discovered in the park ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3
... A cell,s genome maintains its integrity by organizing ... DNA called heterochromatin. In the comparatively simple organism fission ... plays an essential role in assembling heterochromatin, which keeps ... Central to this process is a large protein complex ...
... of vitamin C were associated with higher levels of high ... issues or death for heart failure patients, in research presented ... to those with high vitamin C intake from food, heart ... intake were 2.4 times more likely to have higher levels ...
... The hermaphroditic cleaner shrimp Lysmata amboinensis usually ... structure. New research published in BioMed Central,s open access journal ... any group larger than two, viciously attack and kill each ... amboinensis are protandric simultaneous hermaphrodites. This means that they ...
Cached Biology News:CSHL team solves a protein complex's molecular structure to explain its role in gene silencing 2Low vitamin C levels may raise heart failure patients' risk 2Violent passions -- jealous cleaner shrimp murder their rivals 2
Request Info...
Polyclonal Antibody to SHPRH...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biology Products: